Lightstone Ventures
Brendan Kelly, PhD, has a wealth of experience in the life sciences industry. Currently serving as Vice President at Lightstone Ventures, Brendan previously held key roles at companies such as A2A Pharmaceuticals and Q32 Bio Inc. Brendan also worked as a Life Sciences Consultant at L.E.K. Consulting and conducted postdoctoral research at Stanford University and University Health Network. Brendan's research focuses on drug discovery and optimization, particularly in the field of neurological drugs targeting G protein-coupled receptors (GPCRs).
This person is not in the org chart
Lightstone Ventures
Lightstone Ventures is a global venture capital fund dedicated to translating novel scientific breakthroughs into clinically and commercially meaningful therapies. We invest in biotech and medtech companies pioneering the big ideas poised to transform patient outcomes. We were founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary bring innovative therapeutics and technologies to the people who need them most. Our investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. We have offices in Boston, Mass., Menlo Park, Calif., and Dublin, Ireland. For more information, visit www.lightstonevc.com.